A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro

被引:29
作者
Srinivasan, M
Wardrop, RM
Gienapp, IE
Stuckman, SS
Whitacre, CC
Kaumaya, PTP
机构
[1] Ohio State Univ, Coll Med Obstet & Gynecol, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Biol Sci, Dept Microbiol, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
[4] Ohio State Univ, Coll Med & Publ Hlth, Dept Obstet & Gynecol, Columbus, OH 43210 USA
关键词
D O I
10.4049/jimmunol.167.1.578
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Complete activation of T cells requires two signals: an Ag-specific signal delivered via the TCR by the peptide-MHC complex and a second costimulatory signal largely provided by B7:CD28/CTLA-4 interactions. Previous studies have shown that B7 blockade can either ameliorate experimental autoimmune encephalomyelitis by interfering with CD28 signaling or exacerbate the disease by concomitant blockade of CTLA-4 interaction. Therefore, we developed a functional CD28 mimic to selectively block B7:CD28 interactions. The design, synthesis, and structural and functional properties of the CD28 free peptide, the end group-blocked CD28 peptide, and its retro-inverso isomer are shown. The synthetic T cell-costimulatory receptor peptides fold into a polyproline type II helical structure commonly seen in regions of globular proteins involved in transient protein-protein interactions. The binding determinants of CD28 can be transferred onto a short peptide mimic of its ligand-binding region. The CD28 peptide mimics effectively block the expansion of encephalitogenic T cells in vitro suggesting the potential usefulness of the peptides for the treatment of autoimmune disease conditions requiring down-regulation of T cell responses. The Journal of Immunology, 2001.
引用
收藏
页码:578 / 585
页数:8
相关论文
共 51 条
[11]  
GOODMAN M, 1992, BIOORG KHIM+, V18, P1375
[12]   Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions [J].
Greene, JAL ;
Leytze, GM ;
Emswiler, J ;
Peach, R ;
Bajorath, J ;
Cosand, W ;
Linsley, PS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (43) :26762-26771
[13]   Biotechnological agents for the immunotherapy of multiple sclerosis - Principles, problems and perspectives [J].
Hohlfeld, R .
BRAIN, 1997, 120 :865-916
[14]  
Inaba M, 1999, J IMMUNOL, V163, P1315
[15]   A RATIONALLY DESIGNED CD4 ANALOG INHIBITS EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS [J].
JAMESON, BA ;
MCDONNELL, JM ;
MARINI, JC ;
KORNGOLD, R .
NATURE, 1994, 368 (6473) :744-746
[16]   IMMOBILIZATION OF PROTEINS TO A CARBOXYMETHYLDEXTRAN-MODIFIED GOLD SURFACE FOR BIOSPECIFIC INTERACTION ANALYSIS IN SURFACE-PLASMON RESONANCE SENSORS [J].
JOHNSSON, B ;
LOFAS, S ;
LINDQUIST, G .
ANALYTICAL BIOCHEMISTRY, 1991, 198 (02) :268-277
[17]   Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease [J].
Karandikar, NJ ;
Vanderlugt, CL ;
Bluestone, JA ;
Miller, SD .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 89 (1-2) :10-18
[18]   CTLA-4: A negative regulator of autoimmune disease [J].
Karandikar, NJ ;
Vanderlugt, CL ;
Walunas, TL ;
Miller, SD ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :783-788
[20]   The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains [J].
Kay, BK ;
Williamson, MP ;
Sudol, P .
FASEB JOURNAL, 2000, 14 (02) :231-241